A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs Fremanezumab (Primary)
  • Indications Migraine
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms HALO-EM
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 09 Sep 2017 Positive efficacy results from pivotal phase III HALO studies (HALO-CM and HALO-EM) as well as data from patient-reported outcomes tools in the chronic migraine trial, presented at the 2017 18th Congress of the International Headache Society (IHC) in Vancouver, Canada, according to a Teva Pharmaceuticals media release.
    • 09 Sep 2017 Results published in a Teva Pharmaceuticals media release.
    • 23 Aug 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top